Mablink is present at BIO-Europe 2021
Edouard LEROY Chief Business Officer of Mablink, participates (digitally) in the next edition of the event BIO-Europe, held as a digital event from October 25 to 28, 2021. BIO-Europe is …
Newsroom
La Tribune fait le portrait de Mablink Bioscience à ses lecteurs
Dans un article paru le vendredi 30 septembre 2021, dans le cadre de sa série “Les biotechs à suivre”, le quotidien La Tribune fait le portrait de Mablink Bioscience, des …
Mablink presents at the digital 9th Antibody Industrial Symposium (June 22-25, 2021)
Mablink presents at the digital 9th Antibody Industrial Symposium (June 22-25, 2021) Our Chief Scientific Officer, Dr Warren Viricel, is giving a presentation at the 9th virtual Antibody Industrial Symposium …
Mablink Bioscience, the next generation ADC company, raises €4 Million from a syndicate of private investors
Mablink Bioscience to move forward its ADC pipeline targeted at cancers with high unmet medical needs Lyon, France, April 27, 2021 Mablink Bioscience, a company developing the next generation of …
A new scientific article published by Mablink scientists
Mablink’s R&D team authored a scientific article published today (March 9) in the journal “Pharmaceuticals”. The paper “Exatecan Antibody Drug Conjugates based on a hydrophilic polysarcosine Drug-Linker platform” characterizes a …
La presse quotidienne nationale s’empare du thème “ADC”
Le quotidien “Le Figaro” s’est fait l’écho de l’engouement de l’industrie pharmaceutique pour l’approche ADC (anticorps conjugués) dans un article publié le 3 mars : lien vers l’article. Mablink est …
Mablink is invited to present at the 12th annual PEGS Europe Virtual summit (November 9-12, 2020)
Dr. Warren Viricel, our company’s Chief Scientific Officer, is invited to present Mablink’s PSARlink™ drug-linker technology at the 12th annual PEGS Europe Virtual summit (Lisbon, PT) on Tuesday, November 10, …
Mablink presents at the digital Next Generation Bioconjugates Summit (November 2-5, 2020)
Mablink’s Chief Scientific Officer Warren Viricel presents preclinical data of our drug-linker ADC platform based on the topoisomerase I inhibitor Exatecan vs. HER-2 ADC gold standard Enhertu® in a mouse …
Oncology Upward Investment (OUI) jury awards Mablink
On October 14, during the MATWIN board meeting, Mablink’s COO Valérie Attuil was pitching in front of a panel of investors as part of the 2nd Oncology Upward Investment event. …
Mablink presents at World ADC Digital (September 15-18, 2020)
Mablink will present preclinical data of our drug-linker ADC platform based on a topoisomerase I inhibitor vs. gold standard Enhertu in a mouse model of gastric cancer.